A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer

Lynn G. Feun, K. Rajender Reddy, Thomas Scagnelli, Jose M. Yrizarry, Jorge J. Guerra, Edward Russell, Marcy Schwartz, Niramol Savaraj, Alan S. Livingstone, Joe U. Levi, Lennox J. Jeffers, Bach Ardalan, Eugene R. Schiff

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Thirty patients with primary hepatocellular carcinoma or liver metastases were entered into a program of chemoembolization with cisplatin, lipiodol, and escalating doses of thiotepa. Doses of cisplatin were 100/m2, and thiotepa doses ranged from 9 mg/m2 to 24 mg/m2. Two of three patients with ocular melanoma had partial responses in the liver metastases for 3+ and 16 months. In patients with either hepatocellular carcinoma (15 patients) or primary cholangiocarcinoma of the liver (three patients), there were two partial responses, for 22 and 33 months. Five patients had minor responses: four with a 40% reduction in tumor and one with a mixed response. There were four early deaths, which involved sepsis in two patients, respiratory failure in one, and acute myocardial infarction in one. Otherwise, toxicity was tolerable and reversible and included abdominal pain and transient elevation of serum creatinine, bilirubin, and transaminases. Less common toxicities included ototoxicity and peripheral neuropathy. Chemoembolization of the liver with cisplatin, thiotepa, and lipiodol can produce responses, but toxicity can be significant. The recommended starting phase II dose for future studies is thiotepa 24 mg/m2 and cisplatin 100 mg/m2.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number4
StatePublished - Aug 1 1999


  • Chemoembolization
  • Cisplatin
  • Liver Cancer
  • Thiotepa

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer'. Together they form a unique fingerprint.

Cite this